Compare RIO & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIO | GSK |
|---|---|---|
| Founded | 1873 | 1715 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.3B | 95.3B |
| IPO Year | N/A | N/A |
| Metric | RIO | GSK |
|---|---|---|
| Price | $81.06 | $49.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $85.00 | N/A |
| AVG Volume (30 Days) | 3.0M | ★ 3.7M |
| Earning Date | 07-30-2025 | 02-04-2026 |
| Dividend Yield | ★ 4.58% | 3.40% |
| EPS Growth | N/A | ★ 118.57 |
| EPS | ★ 6.28 | 1.79 |
| Revenue | ★ $53,729,000,000.00 | $43,237,357,842.00 |
| Revenue This Year | $7.31 | $6.56 |
| Revenue Next Year | $3.52 | $5.13 |
| P/E Ratio | ★ $12.90 | $27.35 |
| Revenue Growth | N/A | ★ 2.73 |
| 52 Week Low | $51.67 | $31.72 |
| 52 Week High | $81.17 | $49.44 |
| Indicator | RIO | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 79.66 | 58.78 |
| Support Level | $74.70 | $48.15 |
| Resistance Level | $81.17 | $49.23 |
| Average True Range (ATR) | 1.10 | 0.61 |
| MACD | 0.50 | -0.08 |
| Stochastic Oscillator | 97.33 | 78.52 |
Rio Tinto is a global diversified miner. Iron ore is the dominant commodity, with significantly lesser contributions from copper, aluminum, diamonds, gold, and industrial minerals. The 1995 merger of RTZ and CRA, via a dual-listed structure, created the present-day company. The two operate as a single business entity, with shareholders in each company having equivalent economic and voting rights. Major assets included the Pilbara iron ore operations, a 30% stake in the Escondida copper mine, 66%-ownership of the Oyu Tolgoi copper mine in Mongolia, the Weipa and Gove bauxite mines in Australia, and six hydro-powered aluminum smelters in Canada.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.